Catriona Yale, Chief Development Officer at Akero Therapeutics, Inc. (AKRO), sold 16,210 shares at $54.80 ($876K) on 2025-06-16, disclosed to the SEC on 2025-06-20.
Scheduled sale ($876k) by Chief Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $53.78 | 6,210 | $334K | 38.1% |
| 2 | $53.78 | 6,210 | $334K | 38.1% |
| 3 | $54.80 | 2,895 | $159K | 18.1% |
| 4 | $55.52 | 895 | $50K | 5.7% |
| Total | $54.06 avg | 16,210 | $876K | 100% |
| Filing → |
| AKRO | SELL | 2025-06-20 | $179K | — | Filing → |
| AKRO | SELL | 2025-06-12 | $151K | — | Filing → |
| AKRO | SELL | 2025-05-19 | $786K | — | Filing → |